— 7 deaths and over 100 serious adverse events reported to FDA after treatment with Vykat XR
August 12, 2026
• 2 min read
Prader-Willi syndrome experts are warning of potential safety risks associated with extended-release diazoxide choline (Vykat XR), a drug approved last year for treating the extreme bouts of hunger experienced by patients with the rare genetic condition.
As of July 31, seven deaths and more than 100 serious adverse events have been reported to the FDA's Adverse Event Monitoring System, according to a statement released Tuesday from the Foundation for Prader-Willi Research, International Prader-Willi Syndrome Organization, and Prader-Willi Syndrome USA.
